Overview
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure.
Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day.
Eligibility
Inclusion Criteria:
- Adults aged 18 years or more
Exclusion Criteria:
- Incapabability of giving informed consent
- Withdrawal of informed consent